Matt Hoffman

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

The 0.2% topical gel, branded as Hyftor by Nobelpharma America, was approved in March 2022, and is indicated for individuals aged 6 years and older with TSC. It is the first topical therapy approved for this population.

The Rafa Laboratories 10-mg midazolam autoinjector is the first in market product of its kind, adding another option for the rescue of individuals with status epilepticus, a condition with crucial time implications in treatment.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and movement disorders.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Chris Winter, MD. [LISTEN TIME: 31 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

The investigational therapy is a twice-daily injectable identical formulation of the protein ghrelin, being assessed in a 2-part trial including individuals who are highly symptomatic within 28 days of brain injury.

Joseph E. Sullivan, MD; Kelly Knupp, MD; Mary Anne Meskis; and Tracy Dixon-Salazar, PhD, share insight into the patient and provider journey of LGS and Dravet syndrome, from diagnosis through treatment.

Data assessing samples of deep cervical lymph node aspirates and blood suggest that germinal center activity was associated with clinical relapses in individuals with neuromyelitis optica spectrum disorder.

Data suggest that long-term treatment with immunosuppression therapies, such as rituximab, is generally appropriate for patients with neuromyelitis optica, though transverse myelitis might indicate a higher risk of relapse post discontinuation.

The AAV1 gene therapy, PBFT02, is being assessed in a phase 1/2 trial called upliFT-D (NCT04747431), which is planned to take place over the course of 24 months in patients with frontotemporal dementia with granulin mutations.

Clene Nanomedicine’s gold nanocrystal suspension treatment showed significant improvements in Low Contrast Letter Acuity and Multiple Sclerosis Functional Composite scores among individuals with relapsing multiple sclerosis.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis.

The deaths, occurring shortly after treatment infusion, were because of acute liver injury, which is a known risk associated with the Novartis gene therapy.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Olwen C. Murphy, MBBCh; and Matthew R. Vogt, MD, PhD. [LISTEN TIME: 40 minutes]

After Reata Pharmaceuticals submitted an analysis from the MOXIe extension study of the investigational agent as part of the NDA submission, the FDA extended the PDUFA date to February 2023.

Lawrence Newman, MD, offered his insight into the findings of a survey conducted by the American Headache Foundation that identified correlations between migraine and mental health conditions.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuromyelitis optica spectrum disorder.

The FDA expressed concerns about the limitations of the data included in the submission, and recommended that Acadia conduct an additional trial in AD psychosis with pimavanserin (Nuplazid).

The Alnylam Pharmaceuticals agent, already approved for the treatment of polyneuropathy in those with hATTR amyloidosis, has now shown promise as a therapeutic option for patients with ATTR amyloidosis with cardiomyopathy.

During a Focused Topic Session at the 2022 Alzheimer’s Association International Conference, NeurologyLive® inquired with a panel of experts about the possibility of exploring a combination approach to Alzheimer disease as the future of treatment.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The monoclonal antibody that preferentially targets Aß oligomers failed to meet either of its coprimary end points—despite favorable results over the placebo group—in individuals who were unimpaired but at risk for AD.

A cohort of more than 2000 older Latin American individuals reported a significant difference in cognitive symptoms when they underwent a positive life change during the early phase of the COVID-19 pandemic.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

After an investigative report published in Science called to question years of research around the existence of an amyloid oligomer known as Aß*56, debates about the amyloid hypothesis have been reignited in the Alzheimer community.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Darin T. Okuda, MD, and Karin Cook. [LISTEN TIME: 55 minutes]

Get caught up on some of the latest news in Alzheimer disease and dementia, with data updates and expert insights, all in one place from the NeurologyLive® team.

The oral suspension, marked as Ztalmy by developer Marinus, is the first drug approval for cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (also known as CDD), given the greenlight in March. The agent is now available as of July 28, 2022.

Those with an optimal Life's Simple 7 score had roughly a 30% to 43% lower lifetime stroke risk than those with an inadequate Life's Simple 7 categorization, corresponding to almost 6 additional years of stroke-free life.